On October 18, 2016, the Friends of Cancer Research and the Duke-Margolis Center for Health Policy will convene a half-day forum bringing together clinicians, originator and biosimilar drug sponsors, advocates, regulators, and payers to tackle remaining uncertainty surrounding the future of the U.S. biosimilars market.  The Forum, “The Future of the U.S. Biosimilars Market: Development, Education, and Utilization” will be held in Washington, D.C. at the Washington Marriott – Georgetown, 1221 22nd Street, NW.

Draft Meeting Agenda 

9:00 a.m. – Welcome and Introduction

     – Jeff Allen, Friends of Cancer Research

9:10 a.m. – Session I: The Current Landscape of Biosimilars Development, Regulatory Review, and Stakeholder Education

9:10 a.m. – FDA’s Perspective on the Regulation of Biosimilars

     – Leah Christl, U.S. Food and Drug Administration

9:30 a.m. – Manufacturer Experiences with Biosimilar Development

     – Carlos Sattler, Sandoz, Inc.

9:50 a.m.– Panel Discussion

Moderator: Robert Rifkin, The U.S. Oncology Network

Emily Alexander, AbbVie, Inc.

Lisa Bell, Coherus BioSciences

Leah Christl, U.S. Food and Drug Administration

Kristen Santiago, Cancer Support Community

Carlos Sattler, Sandoz, Inc.

Kimberly Wright, Susan G. Komen

10:20 a.m.– Moderated Discussion and Audience Q&A

10:50 a.m. – Break

11:00 a.m. – Session II: Addressing Challenges in Clinical Decision-Making, Coverage and Reimbursement, and Postmarket Evidence Development

Moderator: Mark McClellan, Robert J. Margolis, MD, Center for Health Policy at Duke University

Elaine Daniels, Pfizer

Jeff Eichholz, Express Scripts

Andrea Ferris, Lungevity

Kevin Haynes, HealthCore LLC

Richard Schilsky, American Society of Clinical Oncology

12:00 p.m.– Moderated Discussion and Audience Q&A

12:30 p.m. – Closing Remarks

     – Mark McClellan, Duke-Margolis

www.focr.org        @CancerResrch

To register, click here.

We look forward to seeing you there!